Kindred Biosciences (KIN) Tops Q4 EPS by 9c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.34), $0.09 better than the analyst estimate of ($0.43).

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c